Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
暂无分享,去创建一个
S. Cerutti | L. Dogliotti | D. Fontana | P. Ardissone | G. Isaia | A. Berruti | G. Reimondo | C. Terrone | A. Angeli | G. Fasolis | R. Tarabuzzi | S. R. Rossetti | S. De Luca | M. Mari | S. Rossetti
[1] K. Carlström,et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens , 1995, Calcified Tissue International.
[2] C. Tyrrell,et al. Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate , 1994, Calcified Tissue International.
[3] P. Kantoff,et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.
[4] M. Parmar,et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.
[5] M. Terris,et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. , 2001, Urology.
[6] L. Dogliotti,et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.
[7] A. Furuta,et al. Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancer , 2000, BJU international.
[8] E. Orwoll,et al. Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.
[9] S. Cerutti,et al. Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. , 2000, Oncology reports.
[10] H. Herr,et al. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. , 2000, The Journal of urology.
[11] D. Kiel,et al. Risk Factors for Longitudinal Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] D. Ferguson,et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.
[13] R. Stege. Potential side‐effects of endocrine treatment of long duration in prostate cancer , 2000, The Prostate. Supplement.
[14] J. Manola,et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.
[15] John T. Wei,et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. , 1999, Urology.
[16] J. Sibilia,et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. , 1999, The Journal of urology.
[17] T. Diamond,et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma , 1998, Cancer.
[18] M. Barry,et al. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. , 1998, The Journal of urology.
[19] N. Mauras,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Testosterone Deficiency in Young Men: Marked Alterations in Whole Body Protein Kinetics, Strength, and Adiposity* , 2022 .
[20] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[21] H. Daniell. Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.
[22] S. Graham,et al. Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma , 1997, Cancer.
[23] P. Ross. Osteoporosis. Frequency, consequences, and risk factors. , 1996, Archives of internal medicine.
[24] T. Diamond,et al. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. , 1995, The Journal of urology.
[25] E. Seeman. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. , 1993, The American journal of medicine.
[26] C. Rosen,et al. Validation of a quantitative food frequency questionnaire for rapid assessment of dietary calcium intake. , 1989, Journal of the American Dietetic Association.
[27] D. Baylink,et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. , 1989, The Journal of clinical endocrinology and metabolism.
[28] D. Wolfe,et al. Nonparametric Statistical Methods. , 1974 .